The global PCSK9 inhibitors industry is witnessing robust development driven by advancements in lipid-lowering therapies and rising cardiovascular disease prevalence. With active innovation pipelines and expanding therapeutic indications, the market outlook remains highly optimistic, underpinned by increasing clinical adoption and regulatory approvals. This PCSK9 inhibitors market trends and...